Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.

Heng SC, Slavin MA, Al-Badriyeh D, Kirsa S, Seymour JF, Grigg A, Thursky K, Bajel A, Nation RL, Kong DC.

J Antimicrob Chemother. 2013 Jul;68(7):1669-78. doi: 10.1093/jac/dkt068. Epub 2013 Mar 13.

PMID:
23485723
2.

Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.

Al-Badriyeh D, Slavin M, Liew D, Thursky K, Downey M, Grigg A, Bajel A, Stewart K, Kong DC.

J Antimicrob Chemother. 2010 May;65(5):1052-61. doi: 10.1093/jac/dkq076. Epub 2010 Mar 17.

PMID:
20237074
3.

Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.

Heimann SM, Cornely OA, Vehreschild MJ, Glossmann J, Kochanek M, Kreuzer KA, Hallek M, Vehreschild JJ.

Mycoses. 2014 Feb;57(2):90-7. doi: 10.1111/myc.12105. Epub 2013 Jun 24.

4.

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA.

Haematologica. 2012 Mar;97(3):459-63. doi: 10.3324/haematol.2011.051995. Epub 2011 Nov 4.

5.

Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.

Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP.

Eur J Haematol. 2008 Dec;81(6):467-74. doi: 10.1111/j.1600-0609.2008.01141.x.

PMID:
18754857
6.

Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.

Cho SY, Lee DG, Choi JK, Lee HJ, Kim SH, Park SH, Choi SM, Choi JH, Yoo JH, Kim YJ, Kim HJ, Min WS, Back H, Kang S, Lee EK.

Clin Ther. 2015 Sep;37(9):2019-27. doi: 10.1016/j.clinthera.2015.06.014. Epub 2015 Jul 15.

7.
8.

Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.

Vehreschild JJ, Rüping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA.

J Antimicrob Chemother. 2010 Jul;65(7):1466-71. doi: 10.1093/jac/dkq121. Epub 2010 Apr 21.

PMID:
20410061
10.

No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation.

Bertz H, Drognitz K, Lübbert M.

Ann Hematol. 2014 Jan;93(1):165-7. doi: 10.1007/s00277-013-1854-6. Epub 2013 Aug 15. No abstract available.

PMID:
23949313
11.
12.

Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.

Lundberg J, Höglund M, Björkholm M, Åkerborg Ö.

Clin Drug Investig. 2014 Jul;34(7):483-9. doi: 10.1007/s40261-014-0199-9.

PMID:
24820968
13.

Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.

Zhao YJ, Khoo AL, Tan G, Teng M, Tee C, Tan BH, Ong B, Lim BP, Chai LY.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):376-86. doi: 10.1128/AAC.01985-15.

14.

A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).

Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA.

J Infect. 2007 Nov;55(5):445-9. Epub 2007 Sep 6.

PMID:
17822770
15.

Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.

Kung HC, Johnson MD, Drew RH, Saha-Chaudhuri P, Perfect JR.

Cancer Med. 2014 Jun;3(3):667-73. doi: 10.1002/cam4.225. Epub 2014 Mar 19.

16.

An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.

Sung AH, Marcella SW, Xie Y.

J Med Econ. 2015 May;18(5):341-8. doi: 10.3111/13696998.2014.1000460. Epub 2015 Mar 2.

PMID:
25524741
17.

Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.

Athanasakis K, Petrakis I, Kyriopoulos J.

J Med Econ. 2013;16(5):678-84. doi: 10.3111/13696998.2013.781028. Epub 2013 Mar 13.

PMID:
23448409
18.

Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.

Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolaños-Meade J, Brown JM, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR.

Am J Health Syst Pharm. 2013 Sep 1;70(17):1518-27. doi: 10.2146/ajhp120599.

19.

Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.

Cho SY, Lee DG, Choi SM, Choi JK, Lee HJ, Kim SH, Park SH, Choi JH, Yoo JH, Kim YJ, Kim HJ, Min WS.

Mycoses. 2015 Sep;58(9):565-71. doi: 10.1111/myc.12357. Epub 2015 Jul 27.

PMID:
26214656
20.

Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.

Michallet M, Gangneux JP, Lafuma A, Herbrecht R, Ribaud P, Caillot D, Dupont B, Moreau P, Berger P, O'Sullivan AK.

J Med Econ. 2011;14(1):28-35. doi: 10.3111/13696998.2010.542393. Epub 2010 Dec 23.

PMID:
21175376

Supplemental Content

Support Center